Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas
NCT ID: NCT07218224
Last Updated: 2025-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-Fluorocholine for the Detection of Parathyroid Adenomas
NCT03764007
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
NCT04895631
FCH PET/MRI Parathyroid Localization
NCT03324893
18F-fluorocholine PET/CT for Hyperparathyroidism
NCT04316845
Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas
NCT02432599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-Fluorocholine (FCH)
A dose of 4-7 millicurie (mCi) +/- 10% of radiotracer 18F-Fluorocholine (FCH) manufactured at UCSF will be given intravenously.
Positron emission tomography (PET)
A scan is a procedure that produces images of organs and tissues used in conjunction with a radiotracer.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Evidence of primary hyperparathyroidism.
3. Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thomas Hope
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Hope
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Hope, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25-44398
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.